Loading...
Loading...
On Friday, JP Morgan upgraded shares of
Teva PharmaceuticalsTEVA from Underweight to Neutral and raised the profit target to $49.
Analyst Chris Schott is encouraged by “favorable initial Copaxone 3x weekly trends and the potential for additional cost cutting activity,” but remains “less enthusiastic around Teva's organic growth prospects and its P&L reliance on Copaxone.”
Schott expects Teva management's “willingness to consider larger business development opportunities will be well received.”
Shares of Teva are up 21 percent year-to-date and up 1.8 percent to $48.82 during Friday's session.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in